Advances in adjuvant therapy against acute bacterial meningitis

Virginia Pomar, Sergi Martínez, Roger Paredes, Pere Domingo

    Research output: Contribution to journalReview articleResearchpeer-review

    7 Citations (Scopus)


    Death and co-morbidity derived from acute bacterial meningitis remain unacceptably high and are mainly related to immune-mediated cerebral dysfunction. Cerebral edema, hydrocephalus and ischaemic cerebrovascular events are severe complications that eventually occur following the activation of a complex network of cytokines, chemokines, proteases and oxidants released after cerebrospinal fluid infection. The caspase pathway appears to play a central role in the induction and amplification of the host inflammatory response. Such overactive immune reactions induce brain cell damage but, importantly, they may potentially be blocked. Several agents have been developed aiming to counteract the deleterious effects of such immune imbalance. These drugs are candidates to become adjuvant therapy against acute bacterial meningitis in the future, in addition to dexametasone. We review the current state-of-art of bacterial meningitis adjuvant therapy, including caspase inhibitors, antioxidants, poly (ADP-ribose) polymerase inhibitors, inhibitors of lipid peroxidation and metalloproteinase inhibitors. © 2004 Bentham Science Publishers Ltd.
    Original languageEnglish
    Pages (from-to)303-309
    JournalCurrent Drug Targets - Infectious Disorders
    Issue number4
    Publication statusPublished - 1 Dec 2004


    • Adjuvant therapy
    • Apoptosis
    • Bacterial meningitis
    • Lipid peroxidation
    • Metalloproteinase
    • Necrosis


    Dive into the research topics of 'Advances in adjuvant therapy against acute bacterial meningitis'. Together they form a unique fingerprint.

    Cite this